Company Profile

Calando Pharmaceuticals Inc (AKA: Insert Therapeutics)
Profile last edited on: 9/19/19      CAGE:       UEI:

Business Identifier: Targeted therapeutics for the development of nanoparticle drug formulations.
Year Founded
2000
First Award
2006
Latest Award
2006
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

225 South Lake Avenue 3rd Floor
Pasadena, CA 91101
   (626) 683-7200
   info@calandopharma.com
   www.calandopharma.com
Location: Single
Congr. District: 27
County: Los Angeles

Public Profile

Previously doing business as Insert Therapeutics before changing its name to Calando Pharmacueticals, the firm was anchored primarily in work coming out of Cal tech. As of October 2009, Calando has operated as a majority-owned subsidiary of Arrowhead Research Corporation. The firm went into Chapter 7 Bankruptcy in 2014 and soon after relocated and is again open for business again with a different but credentialed management team. Calando Pharmaceuticals Inc is a biopharmaceutical company focused on creating targeted therapeutics using its patented and proprietary cyclodextrin-based polymer technologies for the development of nanoparticle drug formulations. Calando’s initial emphasis has been to bring targeted siRNA and small molecule therapeutics to the clinic for oncology applications; however, the technologies are not limited to these classes of molecules and are applicable to a very broad range of therapeutic entities and diseases. The Calando technology for RNAi, called RONDEL™, overcomes the significant hurdles to efficient, systemic delivery of siRNA. Calando’s technology for siRNA therapeutics: * Allows for repeat dosing without the risk of immune reactions * Has demonstrated efficient, targeted delivery in animal models * Has overcome the extra- and intra-cellular barriers to siRNA delivery * Has been scaled-up and manufactured for clinical use. In addition to the RNAi technologies and pipeline, Calando Pharmaceuticals has a therapeutic pipeline that involves small molecule dr

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $100,000
Project Title: Design and Delivery of Hybrid Phosphorthioate/phosphodiester siRNA Duplexes

Key People / Management

  Christopher Anzalone -- Chief Executive Officer

  Larry Stambaugh -- President

  James Hamilton

  Jeremy D Heidel

  Thomas Schluep -- Chief Scientific Officer

Company News

There are no news available.